DFW Capital Partners announced today that on August 26, 2013 it completed an equity investment in the parent entity of Sebela International, Ltd and Sebela Pharmaceuticals, Inc. (“Sebela”), a newly-formed specialty pharmaceutical acquisition and licensing platform. Joining DFW in the equity investment was Sebela’s executive management team, members of which had previously led a former DFW portfolio company, Alaven Pharmaceutical. Also investing is Altiva Capital, led by Bala Venkataraman, one of DFW’s Operating Affiliates and currently Chairman of Vidara Therapeutics, a DFW portfolio company.
DFW and management’s equity investment was made to support the acquisition of a portfolio of branded prescription pharmaceutical products. Consistent with the successful acquisition and growth strategy of Alaven Pharmaceutical, the Sebela team is focused on acquiring and in-licensing products which no longer fit the strategic and operating objectives of their innovators or current owners. Sebela’s team is highly skilled in developing and implementing marketing, promotional, sales and development efforts around these “non-core” products and breathing new life and sales growth into historically stagnant product lines. DFW and Sebela intend to pursue an acquisition and in-licensing based growth strategy to build Sebela into a leading specialty pharmaceutical company in its core therapeutic markets.
Sebela is headquartered in Dublin, Ireland, with its US operations located in Alpharetta, GA.
About DFW Capital Partners:
DFW Capital Partners is a private equity investment firm focused on lower middle-market companies. The firm concentrates on service companies, with an emphasis on healthcare and outsourced business and industrial support services. DFW is backed by both institutional and high-net worth individual investors, and has established a 20+ year track record of success in building leading companies and delivering superior returns for its investors. DFW is headquartered in Teaneck, NJ, and maintains an office in Chevy Chase, MD. For more information contact Keith Pennell, Managing Partner, at (201) 836-6000.